The Supreme Court Just Closed One Door — But It Did Not Close All of Them
If you used Roundup and later heard the words non-Hodgkin lymphoma from a doctor, you already know what fear feels like. Now you are reading the news that the United States Supreme Court just ruled against a Missouri resident who had the same cancer and the same exposure — and you are wondering whether the courthouse door has been locked in your face. We are going to tell you the truth about what this ruling means, what it does not mean, and what you still have time to do. The short version: one legal theory was shut down. The settlement path was built to survive exactly this outcome. And at least two other legal theories were not directly addressed by the Court and may still have life, depending on the facts of your case and the jurisdiction you are in. But every one of those paths has a clock on it, and some of the proof that decides your case is on a timer that has already started running.
We are Attorney911 — The Manginello Law Firm, PLLC, and we handle toxic tort and product liability cases. This page is not a news article. It is the analysis a senior trial attorney gives a client who just called in crisis after reading the headline. Everything here is written for the person who has the most to lose from misunderstanding what just happened — you.
What FIFRA Preemption Means for Your Specific Case
FIFRA is the federal statute that gives the EPA authority over pesticide registration and labeling. Under this regime, a pesticide cannot be sold in the United States unless the EPA has approved its label. The label is not a suggestion — it is a federally regulated document, and changing it requires EPA review.
The preemption doctrine the Supreme Court invoked works like this: when federal law creates a requirement that conflicts with what state law would require, the federal requirement controls. The majority held that the EPA’s approval of Roundup’s label without a cancer warning created a federal requirement — Monsanto’s label must not bear a cancer warning — and any state-law claim that would impose a duty to warn about cancer directly conflicts with that federal requirement.
This means the specific legal theory that drove the majority of Roundup litigation — that Monsanto failed to warn consumers about cancer risk on the product label — is now preempted. State courts and federal courts across the country are expected to dismiss thousands of pending failure-to-warn lawsuits as a result of this decision. The ruling applies nationwide. It does not matter whether your case was filed in Missouri, California, or any other state — the Supreme Court’s interpretation of federal law binds every court in the country.
But here is what the ruling does not do. It does not foreclose every possible legal theory against Monsanto. It does not shut down the $7.25 billion class-action settlement. It does not say Roundup is safe. It does not say glyphosate does not cause cancer. And it does not eliminate every path to compensation for people who were exposed to Roundup and developed non-Hodgkin lymphoma. What it does is close the most common door — the failure-to-warn door — and redirect everyone toward the doors that remain.
Legal Theories That May Survive the Preemption Ruling
The Supreme Court’s ruling is specifically about failure-to-warn claims — the theory that Monsanto had a duty under state law to put a cancer warning on the Roundup label and failed to do so. The majority held that this theory is preempted by FIFRA because the EPA-approved label does not include a cancer warning and state law cannot impose a conflicting labeling duty.
But not every product liability theory is a failure-to-warn theory. The dossier of theories that may survive, depending on jurisdiction and facts, includes the following:
Design defect. The theory that Roundup is inherently dangerous in its design or formulation — that the product itself is unreasonably dangerous, separate from the question of what the label says. This theory targets the product, not the label. The Supreme Court’s ruling was focused on labeling requirements, and a design-defect claim that does not depend on the content of the label may not be directly preempted by the majority’s reasoning. However, defense counsel will argue that the preemption logic extends to any claim that would require Monsanto to alter the product or its label, and courts will have to decide whether the ruling’s reach extends that far. The viability of design-defect claims varies by jurisdiction and must be assessed case by case.
Negligent testing and fraudulent concealment. These theories target Monsanto’s conduct in studying, suppressing, or misrepresenting glyphosate’s cancer risk — not the content of the product label. If a plaintiff alleges that Monsanto knew its internal science showed a cancer risk and deliberately concealed or misrepresented that information, the claim is about the company’s conduct, not about what words were printed on a bottle of Roundup. Claims grounded in a manufacturer’s research, testing, and disclosure practices — rather than in labeling requirements — may survive preemption because they do not directly conflict with the EPA’s label-approval decision. Whether these theories survive will depend heavily on the specific facts pleaded and the jurisdiction’s preemption analysis.
Class action settlement claims. The $7.25 billion settlement is not a legal theory — it is a compensation mechanism. But it is now the most reliable one. The settlement was negotiated separately from the individual litigation, it does not depend on the survival of any particular tort theory, and it was designed to pay claims regardless of the preemption ruling. For the vast majority of Roundup cancer victims, this is the path that remains open and that must be pursued within the settlement administrator’s deadlines.
The Medicine: Non-Hodgkin Lymphoma and the Proof Problem
Non-Hodgkin lymphoma is the cancer most frequently linked to Roundup in the litigation. It is a cancer of the lymphatic system — the body’s network of lymph nodes, spleen, and other organs that are part of the immune system. It begins in white blood cells called lymphocytes, which normally help the body fight infection. When lymphocytes become abnormal, they can multiply uncontrollably and form tumors.
Diagnostics. Non-Hodgkin lymphoma is diagnosed through a combination of physical examination, blood tests, imaging (CT scans, PET scans), and — critically — a lymph node biopsy with pathology confirmation. The pathology report identifies the specific subtype of non-Hodgkin lymphoma, which matters both for treatment and for any settlement claim tier classification. If you have been diagnosed, your pathology report is the foundational medical document in your case.
Treatment. Treatment varies by subtype and stage but commonly includes chemotherapy, immunotherapy (such as monoclonal antibody drugs), radiation, and in some cases stem cell transplantation. The cost of treatment — particularly for aggressive subtypes requiring induction therapy followed by maintenance therapy or transplant — can reach into the hundreds of thousands of dollars, and in cases requiring stem cell transplant, the cost can exceed a million dollars in medical bills alone. For the settlement claim process, your treatment history and its cost are part of what determines your tier classification.
Latency and the discovery rule. Non-Hodgkin lymphoma associated with glyphosate exposure does not develop overnight. There is a latency period between exposure and diagnosis — the disease can take years to surface after the relevant exposure. This is why the discovery rule matters so much in these cases: if the statute of limitations started on the date of your last Roundup use, many claims would be time-barred before the cancer was even diagnosed. The discovery rule — which many states, including Missouri, apply in toxic exposure cases — starts the clock when you knew or should have known of the injury and its connection to the exposure, not when you were exposed.
The proof problem the defense exploits. Non-Hodgkin lymphoma has causes unrelated to glyphosate — it can arise from genetic factors, other chemical exposures, immune system conditions, and sometimes with no identifiable cause at all. The defense in any Roundup case argues that the plaintiff cannot prove their specific cancer was caused by Roundup rather than by something else or by nothing identifiable. This is the “specific causation” problem, and it is why documented exposure history — how long you used Roundup, how frequently, in what quantities, and through what route (spraying, mixing, direct contact) — is so critical. The settlement structure accounts for this by tiering claims based on exposure duration and intensity, which is why documenting your exposure thoroughly is the single most important thing you can do to maximize your recovery.
What Your Case Is Worth After This Ruling
The Supreme Court’s preemption ruling fundamentally changes the value of Roundup cases. Before the ruling, individual failure-to-warn lawsuits in plaintiff-friendly venues like Missouri produced verdicts in the multi-million-dollar range, including significant punitive damages. That pathway is now largely closed.
The $7.25 billion class-action settlement, spread across tens of thousands of claimants, will produce per-claimant values that are a fraction of what individual verdicts yielded. Based on the settlement structure, individual claimant values are expected to range from approximately $50,000 to $150,000 per claimant, with higher-tier payments for claimants with strong exposure histories and confirmed non-Hodgkin lymphoma diagnoses. These figures are honest estimates based on the arithmetic of dividing a fixed settlement fund across a large claimant pool — they are not guarantees, and individual payments will depend on the specific tier classification the settlement administrator assigns to your claim.
Claimants with strong exposure histories — long duration, high intensity, occupational rather than residential use — and confirmed non-Hodgkin lymphoma diagnoses with clear pathology may receive higher-tier settlement payments. But the leverage of individual trial verdicts, particularly the punitive damages that drove settlement value in venues like Missouri, is now largely extinguished for the failure-to-warn theory.
Any remaining non-preempted theories — design defect, negligent testing, fraudulent concealment — carry significant uncertainty. Their viability varies by jurisdiction and must be assessed case by case. If a non-preempted theory succeeds, the value of that case could be substantially higher than the settlement tier, because it would not be capped by the settlement structure and could include punitive damages in states that permit them. But the path to that outcome is uncertain, case-specific, and not guaranteed.
For families of deceased claimants — people who used Roundup, developed non-Hodgkin lymphoma, and died from the disease — wrongful death claims may still be compensable through the settlement structure. Survival and wrongful death damages are theoretically available through the settlement, and the family of a deceased claimant should pursue this path with the same urgency as a living claimant, because the deadlines do not extend simply because the claimant has passed.
Past results depend on the facts of each case and do not guarantee future outcomes. The figures discussed here are honest estimates based on the settlement structure and the changed legal landscape — they are not promises, and your individual recovery will depend on your specific facts.
The Playbook: What Bayer’s Lawyers Will Do Next
Bayer and its legal teams have been preparing for this ruling. Here are the moves you should expect, and the counter to each:
Play 1: The “your case is dismissed” letter. Bayer’s lawyers will send letters to plaintiffs’ counsel across the country arguing that the Supreme Court’s ruling requires dismissal of all failure-to-warn claims. Some courts will grant these motions quickly. The counter: the ruling addresses failure-to-warn claims tied to labeling — it does not automatically foreclose every theory or the settlement path. If your case includes non-preempted theories, your attorney should oppose blanket dismissal and argue for the survival of design-defect, negligent-testing, or fraudulent-concealment claims. If your case is purely a failure-to-warn claim, the settlement is your path.
Play 2: The settlement tier minimization. The settlement administrator’s incentive structure — whether conscious or systemic — tends toward classifying claims at the lowest qualifying tier, because the fund is finite and every dollar paid to one claimant is a dollar not available for another. The counter: document your exposure with maximum specificity. The difference between a lower tier and a higher tier can be tens of thousands of dollars, and that difference is often determined by the quality and quantity of exposure evidence you submit. Purchase receipts, employment records, coworker statements, and a detailed sworn statement of your usage history are what push you into the higher tier.
Play 3: The “you waited too long” argument. For any non-preempted theory that survives, Bayer will argue the statute of limitations has run. The counter: the discovery rule in toxic exposure cases often starts the clock from the date you knew or should have known of the connection between your cancer and Roundup — not from the date of exposure. Missouri’s five-year statute of limitations is among the most generous in the nation, and the discovery rule may provide additional time. But this is not a reason to wait — it is a reason to act now, while the argument is strongest.
Play 4: The “EPA says it’s safe” defense. Bayer will cite the EPA’s classification of glyphosate as “not likely to be carcinogenic to humans” as proof the product is safe and warnings were unnecessary. The counter: the EPA’s regulatory classification is not a scientific finding that glyphosate cannot cause cancer. The International Agency for Research on Cancer — the World Health Organization’s cancer arm — classified glyphosate as “probably carcinogenic to humans” in 2015. The scientific debate is real and unresolved, and a regulatory classification made under FIFRA is not the same thing as a scientific consensus. But the Supreme Court’s ruling means this argument now plays out in the settlement process and in non-preempted theories, not in failure-to-warn trials.
Your First Steps: What to Do Immediately
Step 1: Determine your settlement eligibility and deadline. If you have been diagnosed with non-Hodgkin lymphoma and have a history of Roundup use, contact an attorney immediately to determine whether you are eligible for the $7.25 billion settlement and what your filing deadline is. The settlement administrator’s deadlines are binding — they are the most urgent clock in your case. Do not assume you have plenty of time. Do not assume the deadline has passed without checking. Find out.
Step 2: Gather your medical records. Request your pathology report, treatment summaries, imaging reports, and all records related to your non-Hodgkin lymphoma diagnosis. These documents are the foundation of your settlement claim and any non-preempted legal theory. Your oncologist’s office or the hospital where you were treated can provide these — request them in writing and follow up.
Step 3: Document your Roundup exposure in detail. Write down everything you can remember about your Roundup use: the brand, the years, the frequency, the setting, the route of exposure. If you have purchase receipts, gather them. If your employer required you to use Roundup, request your employment and personnel records. If family members, coworkers, or neighbors can confirm your usage, ask them to write down what they saw. This evidence degrades — do not wait.
Step 4: Do not sign anything without legal review. If you receive a letter from Bayer’s lawyers, the settlement administrator, or anyone else asking you to sign a release, a settlement agreement, or any other document, do not sign it without having an attorney review it first. A release signed without understanding what you are giving up can permanently forfeit your right to compensation.
Step 5: Do not let the statute of limitations run on non-preempted theories. Even if your failure-to-warn claim is preempted, design-defect, negligent-testing, and fraudulent-concealment theories may survive, depending on your jurisdiction and facts. These theories have their own statute-of-limitations clocks. Missouri’s five-year personal injury statute of limitations — combined with the discovery rule for toxic exposure — may give you time, but only an attorney can tell you how much.
Step 6: Call us. The consultation is free. The call is confidential. We will tell you honestly whether you have a path, what that path is, and what it is worth. If we are not the right fit for your case, we will tell you that too. You can reach us at 1-888-ATTY-911 (1-888-288-9911), 24 hours a day, 7 days a week. You will speak to a live person, not an answering service.
Frequently Asked Questions
Can I still sue Monsanto for my cancer after this ruling?
The most common theory — failure to warn — has been largely foreclosed by the Supreme Court’s ruling. However, other theories including design defect, negligent testing, and fraudulent concealment were not directly addressed by the ruling and may survive depending on your jurisdiction and facts. The $7.25 billion class-action settlement is also still proceeding and is now the primary compensation path for most Roundup cancer victims. You should speak with an attorney immediately to determine which path applies to your specific situation.
What happens to my pending Roundup lawsuit?
If your pending lawsuit is based on failure-to-warn claims, it is likely to face a motion to dismiss from Monsanto’s lawyers citing the Supreme Court’s preemption ruling. Many courts are expected to grant these motions. However, if your case includes non-preempted theories — design defect, negligent testing, fraudulent concealment — your attorney should oppose blanket dismissal and argue for the survival of those claims. If your case is dismissed, the settlement path remains available, provided you meet the settlement administrator’s deadlines.
I was diagnosed with non-Hodgkin lymphoma but never filed a lawsuit. Is it too late?
It may not be too late. Missouri has a five-year statute of limitations for personal injury claims, and many states apply a discovery rule in toxic exposure cases that starts the clock when you knew or should have known of the connection between your cancer and Roundup — not when you were exposed. The $7.25 billion settlement also has its own claim-filing deadlines, which are separate from the statute of limitations. You need to determine your eligibility and deadline immediately — do not assume it is too late without checking, and do not assume you have plenty of time.
How much will I get from the $7.25 billion settlement?
Individual settlement payments are expected to range from approximately $50,000 to $150,000 per claimant, with higher-tier payments for claimants with strong exposure histories and confirmed non-Hodgkin lymphoma diagnoses. The specific amount depends on the tier classification the settlement administrator assigns to your claim, which is based on injury severity, exposure duration, and exposure intensity. These are estimates based on the settlement structure — not guarantees. Your individual recovery will depend on your specific facts and the quality of your documentation.
The Supreme Court said the EPA does not require a cancer warning. Does that mean Roundup is safe?
No. The Supreme Court’s ruling is about legal preemption — whether federal labeling law overrides state tort law — not about whether Roundup causes cancer. The EPA’s classification of glyphosate as “not likely to be carcinogenic to humans” is a regulatory determination, not a scientific consensus. The International Agency for Research on Cancer, which is the World Health Organization’s cancer agency, classified glyphosate as “probably carcinogenic to humans” in 2015. The scientific debate is real and unresolved. The ruling means the EPA’s regulatory position controls what goes on the label — it does not mean the product is safe.
I used a generic glyphosate product, not Roundup brand. Can I still file a claim?
The settlement and the litigation have focused on Monsanto’s Roundup product specifically. If you used a generic glyphosate herbicide manufactured by a different company, your claim may not fall within the Roundup settlement, and different legal considerations apply. You should discuss your specific product usage with an attorney to determine what options are available.
My family member died from non-Hodgkin lymphoma after using Roundup. Can we still pursue a claim?
Yes — survival and wrongful death claims may be compensable through the settlement structure. The family of a deceased claimant should pursue the settlement path with the same urgency as a living claimant, because the deadlines do not extend simply because the claimant has passed. You will need the deceased’s medical records (pathology, treatment history), evidence of their Roundup exposure, and documentation of your status as a surviving family member. Contact an attorney immediately — we handle wrongful death cases and can help you understand your options.
What if I already received a settlement offer from Bayer or the settlement administrator?
Do not accept any settlement offer without having an attorney review it. The settlement administrator’s tier classification system means that the initial offer you receive may not reflect the full value of your claim — particularly if your exposure history is well-documented and supports a higher tier. An attorney can evaluate whether the offer is fair, whether you have grounds to dispute the tier classification, and whether accepting the settlement forfeits any other rights you may have. The consultation is free — there is no cost to having us review an offer before you sign.
Your Next Step
The Supreme Court closed a door. It did not close every door. The settlement is still open. Non-preempted legal theories may still have life. Your right to compensation has not been eliminated — but it is on a clock, and the clock is running.
The most important thing you can do right now is talk to an attorney who understands this litigation, this ruling, and the settlement process. The call is free. The consultation is confidential. You will speak to a live person at any hour of the day or night. And you will not be pressured — you will be told the truth.
Call 1-888-ATTY-911 (1-888-288-9911). Contact us. We do not get paid unless we win your case.
Hablamos Español. Lupe Peña conducts full consultations in Spanish without an interpreter. If your family communicates in Spanish, you will be understood completely — call us today.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Contacting the firm is free and confidential.